You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
先聲藥業(02096.HK)向NextCure授出許可權 潛在收取最高7.45億美元
阿思達克 06-16 23:46
先聲藥業(02096.HK)公布,附屬先聲再明與NextCure(NXTC.US)訂立許可協議。據此,NextCure將擁有SIM0505於大中華區以外全球範圍的權利;NextCure可獲得先聲再明自有的拓撲異構(酉每)I抑制劑「TOPOi」載荷技術;及先聲再明將擁有該新靶點ADC產品於大中華區的相關權利。集團將在潛在的開發階段收取最高7.45億美元的相關付款,包括首付款、開發及銷售里程碑款項,以及額外獲得基於該產品淨銷售額的高至雙位數分級特許權使用費。 SIM0505是一款靶向CDH6,用於治療實體瘤的創新抗體偶聯藥物「ADC」。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account